Supplementary Figure 8. IC50 curves derived from in vitro cytotoxicity measurements of PAL-conjugated trastuzumab-Dxd (SGZ026 and SGZ028) and Enhertu against HER2-positive human breast cancer cells.
Supplementary Figure 7. IC50 curves derived from in vitro cytotoxicity measurements of PAL-conjugated trastuzumab and disitamab ADCs, Aidixi and Enhertu against HER2-positive human breast cancer cells.
Supplementary Figure 2B. Analysis of Disitamab based antibody-drug conjugates (ADCs) with varying Drug-to-Antibody Ratios (DAR) and payload types by HIC.
Supplementary Figure 1. Analytic characterization of purified trastuzumab tagged with NQL tripeptide either at its light chain (panels A and B) or heavy chain (panels C and D) C-terminus, following SDS PAGE analysis (panels A and C) and size exclusion chromatography (panels B and D).